The rise in the use of GLP‐1 agonists like Semaglutide for obesity management has created new challenges for esthetic practitioners, particularly in addressing skin laxity, fat redistribution, and changes in body contour following significant weight loss. Here, GLP1R is linked to obesity disorder.